Related Experiment Video

Updated: Nov 18, 2025

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.4K

The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma

Meng-Ke Fan1,2, Li-Li Qi3, Qi Zhang2

  • 1Department of Orthopedic Oncology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.

Cancer Management and Research
|February 4, 2021
PubMed

Insights

Immune escape via the B7-H1/programmed death-1 (PD-1) axis is crucial in osteosarcoma (OS) progression. Understanding this interaction and B7-H1/PD-1 immunotherapies is key to reducing OS recurrence and metastasis.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Osteosarcoma (OS) recurrence and metastasis remain significant challenges despite improved survival rates.
  • Immune escape within the tumor microenvironment is a critical factor in OS progression.
  • The B7 family of costimulatory molecules regulates immune cell interactions in OS.

Purpose of the Study:

  • To review the expression, function, and regulation of the B7-H1/programmed death-1 (PD-1) axis in osteosarcoma.
  • To compare the advantages and disadvantages of B7-H1/PD-1 immunotherapies for OS.

Main Methods:

  • Literature review of B7-H1/PD-1 axis expression and function in osteosarcoma.
  • Analysis of current B7-H1/PD-1 checkpoint blockade therapies in various malignancies.
  • Comparative assessment of immunotherapy strategies for OS.

Main Results:

  • The B7-H1/PD-1 axis plays a significant role in immune evasion in osteosarcoma.
  • B7-H1/PD-1 checkpoint blockade therapies show promise but require further investigation in OS.
  • Understanding the specific impact of B7-H1/PD-1 on OS is not yet well-defined.

Conclusions:

  • The B7-H1/PD-1 axis is a critical target for overcoming immune escape in osteosarcoma.
  • Further research is needed to optimize B7-H1/PD-1 immunotherapies for osteosarcoma treatment.
  • Targeting the B7-H1/PD-1 pathway offers potential for reducing osteosarcoma recurrence and metastasis.
Keywords:
B7-H1PD-1immunotherapyosteosarcoma

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.0K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

819

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
861
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K